The market for drugs addressing erectile dysfunction has seen marginal growth, rising from $4.12 billion in 2023 to $4.17 billion in 2024, with a CAGR of 1.2%. This growth is linked to the introduction of PDE5 inhibitors and changing societal attitudes towards treatment. By 2028, the market is projected to reach $4.46 billion, with a CAGR of 1.7%. Factors such as the integration of mental health and innovative therapies will influence future growth.
Major Driver In The Drugs For Erectile Dysfunction Market
The erectile dysfunction drug market is experiencing significant growth due to the rising number of chronic diseases, predominantly caused by a sedentary lifestyle. In September 2023, the World Health Organization (WHO) highlighted that chronic diseases account for 74% of global deaths, amounting to 41 million people annually. The prevalence of chronic diseases substantially contributes to the occurrence of erectile dysfunction in men, thereby fueling the demand for erectile dysfunction drugs. This trend is expected to continue, with the market size projected to expand in 2023, 2024, and 2028.
Request A Free Sample Of The Global Drugs For Erectile Dysfunction Market Report
Drugs For Erectile Dysfunction Market Competitive Landscape
Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Limited, Coloplast A/S, Cipla Limited, Endo International plc, Lupin Limited, Glenmark Pharmaceuticals Limited, S.K. Chemicals Co. Ltd., Dong A Pharmaceutical Co. Ltd., Zephyr Surgical Implants, Seelos Therapeutics Inc., Premedon, Meda Pharmaceuticals Inc., Futura Medical plc, Augusta Medical Systems LLC, Vivus Inc., Apricus Biosciences Inc., Bonro Medical Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Post-T-Vac Medical Inc., Adamed Pharma SA, Produtos Quimicos Farmaceuticos Ltda., Metuchen Pharmaceuticals LLC, Revive Pharmaceuticals Pvt. Ltd., Viatris Specialty LLC
Key Drugs For Erectile Dysfunction Market Trend
New drug delivery methods, including pellets and creams, are being adopted in the erectile dysfunction drugs market for improved efficacy and safety. These innovative delivery techniques are expected to expand the market. For instance, in September 2022, Lupin, an India-based pharmaceutical company, introduced Sildenafil oral suspension (10 mg/mL), approved by the United States Food and Drug Administration (FDA). This unique formulation is designed for treating erectile dysfunction with distinctive dosage options.
Get The Full Global Drugs For Erectile Dysfunction Market Report
Drugs For Erectile Dysfunction Market Segmentation
The drugs for erectile dysfunction market covered in this report is segmented –
1) By Drugs: Sildenafil Citrate, Mirodenafil , Vardenafil
2) By Mode of Administration: Oral, Topical, Injections
3) By End users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography:The regions covered in the drugs for erectile dysfunction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the erectile dysfunction (ED) drugs market in 2023.
The Drugs For Erectile Dysfunction Global Market Report 2024 furnishes information about the global drugs for erectile dysfunction market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.
